

Registration number: 01447831

Eli Lilly Group Limited

Annual Report and Financial Statements

for the Year Ended 31 December 2020



Eli Lilly Group Limited
Registration No: 01447831

Contents

Company Information	1
Strategic Report	2 to 3
Directors' Report	4 to 5
Statement of Directors' Responsibilities	6
Independent Auditor's Report	7 to 10
Income Statement	11
Statement of Comprehensive Income	12
Statement of Financial Position	13
Statement of Changes in Equity	14
Notes to the Financial Statements	15 to 21

Eli Lilly Group Limited
Registration No: 01447831

Company Information

Directors M Czapar
L DeMayo Steele

Registered office Lilly House
Basing view
Basingstoke
Hampshire
RG21 4FA
United Kingdom

Auditors Ernst & Young
City Quarter
Lapps Quay
Cork
Ireland

Eli Lilly Group Limited
Registration No: 01447831

Strategic Report for the Year Ended 31 December 2020

The Directors present their strategic report for the year ended 31 December 2020.

Principal activity

The Company's principal activity is as an intermediary holding company for Eli Lilly and Company's subsidiary undertakings operating in the United Kingdom.

Results

The profit for the year, after taxation, amounted to £0 (2019 profit: £135,009,000). There are no other key performance indicators.

Fair review of the business

Eli Lilly Group Limited is a holding company that incurs limited expenses and whose only source of income is dividends from subsidiary undertakings. The directors are satisfied with the Company's performance during the year.

Principal risks and uncertainties

As a holding company, the Company's principal financial risk would arise from a permanent diminution in the value of the Company's subsidiary undertakings.

Due to the current COVID-19 pandemic the company's subsidiary, Eli Lilly and Company Limited, temporarily halted in-person interactions by the company's employees with healthcare providers, which could decrease demand for the company's products. As last year, the financial impact on the company has not been material to date, given the rapid and evolving nature of the virus, however COVID-19 could still potentially negatively affect the company's results of operations, financial condition, liquidity and cash flows in future periods. The degree to which COVID-19 affects the company will depend on developments that are highly uncertain and beyond the company's knowledge or control, including, but not limited to, the duration and severity of the pandemic, the actions taken to reduce its transmission, and the speed with which, and extent to which, more stable economic and operating conditions resume.

Eli Lilly Group Limited
Registration No: 01447831

Strategic Report for the Year Ended 31 December 2020

Section 172 statement

The directors of Eli Lilly Group Limited consider, both individually and together, that they have acted in the way they consider good faith, would be most likely to promote the success of the company for the benefit of its members as a whole having regard to the stakeholders and matters set out in s172(1)(a-f) of the Companies Act. The decisions made by the company during the year ending 31 December 2020 have been made with the objective; to have a long term beneficial impact on the company, to develop strong value adding business relationships with the company's stakeholders, to take into account the wider impact on the companies' actions on the environment and, to be ethical and maintain the high levels of business conduct.

The company, as an intermediate holding company, has no employees or suppliers and as such the directors primarily consider the interest of the sole member, and ultimate parent company, Eli Lilly and Company with regard to performing their duties on matters set out in section 172 as outlined below:

The key board decisions approved during the year were made in line with the strategic goals and objectives of both the Company and the ultimate parent company Eli Lilly and Company.

Approved by the Board on 26 July 2021 and signed on its behalf by:

Michael C Czapar
Czapar
M Czapar
Director

Digitally signed by
Michael C Czapar
Date: 2021.07.28
14:29:56 +01'00'

Eli Lilly Group Limited
Registration No: 01447831

Directors' Report for the Year Ended 31 December 2020

The Directors present their report and the financial statements for the year ended 31 December 2020.

Directors of the Company

The directors who held office during the year were as follows:

H Bennett - Company secretary and director (resigned 11 February 2021)

N Lemen (resigned 1 January 2021)

A Diaz-Granados (resigned 5 July 2021)

The following directors were appointed after the year end:

M Czapar (appointed 1 January 2021)

L DeMayo Steele (appointed 5 July 2021)

Dividends

Nil dividends were paid in the year. (2019 : £135,000,000).

Going concern

The company is an intermediate holding company and therefore its going concern should be considered with reference to the going concern of its subsidiaries, primarily Eli Lilly and Company Limited. Based upon the directors' knowledge at the date of this report, the COVID-19 pandemic is not expected to represent a significant risk to the Company's liquidity or use of the going concern assumption.

The directors have no reason to believe that a material uncertainty exists that may cast significant doubt about the ability of the company to continue as a going concern. The company participates in the group's centralised treasury arrangements and so shares banking arrangements with its parent and fellow subsidiaries. Accordingly, the directors continue to adopt the going concern basis in preparing the Annual Report and financial statements for the year ended 31 December 2020.

Disclosure of information to the auditors

Each Director has taken steps that they ought to have taken as a Director in order to make themselves aware of any relevant audit information and to establish that the Company's auditors are aware of that information. The Directors confirm that there is no relevant information that they know of and of which they know the auditors are unaware.

Appointment of auditors

In accordance with section 485 of the companies Act 2006, a resolution is to be proposed as the Annual General Meeting for reappointment of Ernst & Young as auditor of the Company.

Eli Lilly Group Limited
Registration No: 01447831

Directors' Report for the Year Ended 31 December 2020

Subsequent events

Following confirmation of the dividend declared by Eli Lilly and Company Limited on 26 July 2021 of £100,000,000 to Eli Lilly Group Limited, the company declared a dividend for £100,000,000 to be paid on 2 August 2021.

Approved by the Board on 26 July 2021 and signed on its behalf by:

Michael C Czapar
Czapar.
M Czapar
Director

Digitally signed by
Michael C Czapar
Date: 2021.07.28
14:30:26 +01'00'

Eli Lilly Group Limited
Registration No: 01447831

Statement of Directors' Responsibilities

The Directors are responsible for preparing the Annual Report and the financial statements in accordance with applicable law and regulations.

Company law requires the Directors to prepare financial statements for each financial year. Under that law the Directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the Directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Company and of the profit or loss of the Company for that period. In preparing these financial statements, the Directors are required to:

- select suitable accounting policies and apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards has been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business.

The Directors are responsible for keeping adequate accounting records that are sufficient to show and explain the Company's transactions and disclose with reasonable accuracy at any time the financial position of the Company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Digitally signed by
Michael C Czapar
Date: 2021.07.28
14:30:58 +01'00'

M Czapar
Director



INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF ELI LILLY GROUP LIMITED

Opinion

We have audited the financial statements of Eli Lilly Group Limited for the year ended 31 December 2020 which comprise the Income Statement, Statement of Comprehensive Income, the Statement of Financial Position, the Statement of Changes in Equity, and the related notes 1 to 12, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards including FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" (United Kingdom Generally Accepted Accounting Practice)".

In our opinion, the financial statements:

- give a true and fair view of the company's affairs as at 31 December 2020 and of its result for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of 12 months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report. However, because not all future events or conditions can be predicted, this statement is not a guarantee as to the company's ability to continue as a going concern.

Other information

The other information comprises the information included in the Annual Report, other than the financial statements and our auditor's report thereon. The directors are responsible for the other information contained within the annual report.



INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF ELI LILLY GROUP LIMITED (Continued)

Other information (continued)

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in this report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of the other information, we are required to report that fact.

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the strategic report and the directors' report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the strategic report and directors' report have been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the strategic report or directors' report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

- adequate accounting records have not been kept or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of directors' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.

Responsibilities of directors

As explained more fully in the statement of directors' responsibilities on page 6, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF ELI LILLY GROUP LIMITED (Continued)

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Explanation as to what extent the audit was considered capable of detecting irregularities, including fraud

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect irregularities, including fraud. The risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery or intentional misrepresentations, or through collusion. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below. However, the primary responsibility for the prevention and detection of fraud rests with both those charged with governance of the entity and management.

Our approach was as follows:

- We obtained an understanding of the legal and regulatory frameworks that are applicable to the company and determined that the most significant are FRS 102, the UK Companies Act 2006 and relevant UK direct and indirect tax regulations. In addition, we concluded that there are certain significant laws and regulations that may have an effect on the determination of the amounts and disclosures in the financial statements and those laws and regulations relating to health and safety, environmental, competition law, anti-bribery and corrupt practices and General Data Protection Requirements;
- We understood how the company is complying with those frameworks by making enquiries of management. We corroborated our enquires through reading the board minutes, and we noted that there was no contradictory evidence;
- We assessed the susceptibility of the company's financial statements to material misstatement, including how fraud might occur by inquiry of management, those charged with governance and others within the entity, as to whether they had knowledge of any actual or suspected fraud. Where this risk was considered higher, we performed audit procedures to address the fraud risk. These procedures included testing manual journals and were designed to provide reasonable assurance that the financial statements were free from fraud or error;
- Based on this understanding we designed our audit procedures to identify non-compliance with such laws and regulations. Our procedures involved:
 - Enquiry of management and those charged with governance as to any fraud identified or suspected in the period, any actual or potential litigation or claims or breaches of significant laws or regulations applicable to the company;
 - Auditing the risk of management override of controls, through testing of a sample of journal entries and other adjustments for appropriateness;



INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF ELI LILLY GROUP LIMITED (Continued)

Explanation as to what extent the audit was considered capable of detecting irregularities, including fraud

- Enquiry of management, coupled with testing of journal entries, in order to identify and understand any significant transactions outside of the normal course of business;
- Challenging the judgements made by management through corroborating the basis for those judgements and considering contradicting evidence; and
- Reading financial statement disclosures and testing to supporting documentation to assess compliance with applicable laws and regulations.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at <https://www.frc.org.uk/auditorsresponsibilities>. This description forms part of our auditor's report.

Use of our report

This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Ian Gregory (Senior Statutory Auditor)
for and on behalf of Ernst & Young Chartered Accounts, Statutory Auditor

Cork
Ireland

Date: 29 July 2021

Eli Lilly Group Limited
Registration No: 01447831

Income Statement for the Year Ended 31 December 2020

	Note	2020 £ 000	2019 £ 000
Turnover		-	-
Administrative expenses		-	11
Operating profit	3	-	11
Income from shares in group undertakings		-	135,000
Profit before tax		-	135,011
Taxation	5	-	(2)
Profit for the financial year		-	135,009

Eli Lilly Group Limited
Registration No: 01447831

Statement of Comprehensive Income for the Year Ended 31 December 2020

	Note	2020 £ 000	2019 £ 000
Profit for the year		<u>-</u>	<u>135,009</u>
Total comprehensive income for the year		<u><u>-</u></u>	<u><u>135,009</u></u>

Eli Lilly Group Limited
Registration No: 01447831

Statement of Financial Position at 31 December 2020

	Note	2020 £ 000	2019 £ 000
Fixed assets			
Investments	6	103,223	103,223
Current assets			
Debtors	7	5,269	5,271
Creditors: Amounts falling due within one year	8	-	(2)
Net current assets		<u>5,269</u>	<u>5,269</u>
Net assets		<u>108,492</u>	<u>108,492</u>
Capital and reserves			
Called up share capital	9	8,350	8,350
Other reserves	9	41,771	41,771
Profit and loss account		<u>58,371</u>	<u>58,371</u>
Total equity		<u>108,492</u>	<u>108,492</u>

Approved and authorised by the Board on 26 July 2021 and signed on its behalf by:

Michael C Czapar
Digitally signed by
Michael C Czapar
Date: 2021.07.28
14:50:41 +01'00'

M Czapar
Director

Eli Lilly Group Limited
Registration No: 01447831

Statement of Changes in Equity for the Year Ended 31 December 2020

	Share capital £ 000	Other reserves £ 000	Profit and loss account £ 000	Total £ 000
At 1 January 2020	8,350	41,771	58,371	108,492
At 31 December 2020	8,350	41,771	58,371	108,492

	Share capital £ 000	Other reserves £ 000	Profit and loss account £ 000	Total £ 000
At 1 January 2019	8,350	41,771	58,362	108,483
Profit for the year	-	-	135,009	135,009
Total comprehensive income	-	-	135,009	135,009
Dividends	-	-	(135,000)	(135,000)
At 31 December 2019	8,350	41,771	58,371	108,492

The notes on pages 15 to 21 form an integral part of these financial statements.

Eli Lilly Group Limited
Registration No: 01447831

Notes to the Financial Statements for the Year Ended 31 December 2020

1 General information

The company is a private company limited by share capital incorporated in United Kingdom.

The address of its registered office is:

Lilly House
Basing view
Basingstoke
Hampshire
RG21 4FA
United Kingdom

These financial statements were authorised for issue by the Board.

2 Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

Eli Lilly Group Limited is a limited liability company incorporated in England. The registered Office is Lilly House, Priestley Road, Basingstoke, Hampshire, RG24 9NL.

The financial statements of Eli Lilly Group Limited were approved for issue by the Board of Directors on the date shown on the Statement of financial position.

These financial statements were prepared in accordance with Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

The financial statements are prepared in sterling which is the functional currency of the group and rounded to the nearest £'000.

Eli Lilly Group Limited
Registration No: 01447831

Notes to the Financial Statements for the Year Ended 31 December 2020

2 Accounting policies (continued)

Going concern

The company is an intermediate holding company and therefore its going concern should be considered with reference to the going concern of its subsidiaries, primarily Eli Lilly and Company Limited. Based upon the directors' knowledge at the date of this report, the COVID-19 pandemic is not expected to represent a significant risk to the Company's liquidity or use of the going concern assumption.

The company participates in the group's centralised treasury arrangements and so shares banking arrangements with its parent and fellow subsidiaries. There is no reason to believe that a material uncertainty exists that may cast significant doubt about the ability of the company to continue as a going concern. Accordingly, the directors continue to adopt the going concern basis in preparing the Annual Report and financial statements for the year ended 31 December 2020.

Name of the Parent group

The consolidated financial statements of Eli Lilly and Company can be obtained from Eli Lilly and Company, Lilly Corporate Centre, Indianapolis, Indiana, USA.

Summary of disclosure exemptions

The company satisfies the criteria of being a qualifying entity under FRS102. Its financial statements are consolidated into the financial statements of its ultimate parent, Eli Lilly and Company, which can be obtained from the address given in note 12. As such, advantage has been taken of the following exemptions under FRS102 for qualifying entities:

The company has taken advantage of the exemption within FRS 102 not to present a cash flow statement. The cash flows of the company have been included in the financial statements of the ultimate parent undertaking.

Group accounts not prepared

The company is exempt from the obligation to prepare group financial statements by virtue of section 401 of the Companies Act 2006. Consequently these financial statements present the results of the company as an individual undertaking and not of its group.

The results of the Company are included in the consolidated financial statements of Eli Lilly and Company, which is incorporated in the United States of America.

Tax

The tax expense for the period comprises current tax.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Investments

Investments are valued at cost. The carrying values of investments in subsidiary undertakings are reviewed for impairment if events indicate that the carrying value may not be recoverable.

Eli Lilly Group Limited
Registration No: 01447831

Notes to the Financial Statements for the Year Ended 31 December 2020

2 Accounting policies (continued)

Borrowings

Interest-bearing borrowings are initially recorded at fair value, net of transaction costs. Interest-bearing borrowings are subsequently carried at amortised cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognised as a charge to the Income Statement over the period of the relevant borrowing.

Interest expense is recognised on the basis of the effective interest method and is included in interest payable and similar charges.

Borrowings are classified as current liabilities unless the Company has an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.

Dividends

Dividend distribution to the company's shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

Dividend Income is recognised when the right to receive payment is established.

3 Operating profit

All audit fees are paid by Eli Lilly and Company Limited.

4 Directors' remuneration

Directors' remuneration has been borne by Eli Lilly and Company Limited. The directors of the company are also directors or officers of other companies within the Eli Lilly and Company group and these directors' services to the company do not occupy a significant amount of their time. As such the directors do not consider that they have received any remuneration for their incidental services to the company for the years ended 31 December 2020 and 31 December 2019.

5 Taxation

Tax debited in the income statement

	2020 £ 000	2019 £ 000
Current taxation		
UK corporation tax	-	2
Total current income tax	-	2

The tax on profit before tax for the year is the same as the standard rate of corporation tax in the UK of 19% (2019 - 19%).

The differences are reconciled below:

Eli Lilly Group Limited
Registration No: 01447831

Notes to the Financial Statements for the Year Ended 31 December 2020

5 Taxation (continued)

	2020 £ 000	2019 £ 000
Profit before tax	-	135,011
Corporation tax at standard rate	-	25,652
Tax (decrease) from effect of dividends from UK companies	-	(25,650)
Total tax charge	-	2

6 Investments in subsidiaries, joint ventures and associates

	2020 £ 000	2019 £ 000
Investments in subsidiaries	103,223	103,223

Details of undertakings

Details of the investments in which the company holds 20% or more of the nominal value of any class of share capital are as follows:

Eli Lilly Group Limited own 100% of the ordinary share capital of the following subsidiaries all of which are registered in England and Wales:

Undertaking	Country of incorporation	Holding	Proportion of voting rights and shares held	
			2020	2019
Subsidiary undertakings				
Eli Lilly and Company Limited	UK	Ordinary Share Capital	100%	100%
Lilly Industries Limited *	UK	Ordinary Share Capital	100%	100%
Eli Lilly (Basingstoke) Limited *	UK	Ordinary Share Capital	100%	100%
Eli Lilly Leasing Limited *	UK	Ordinary Share Capital	100%	100%
Eli Lilly Property Limited *	UK	Ordinary Share Capital	100%	100%
Eli Lilly Resources Limited *	UK	Ordinary Share Capital	100%	100%

Eli Lilly Group Limited
Registration No: 01447831

Notes to the Financial Statements for the Year Ended 31 December 2020

6 Investments in subsidiaries, joint ventures and associates (continued)

Greenfield Pharmaceuticals Limited *	UK	Ordinary Share Capital	100%	100%
Lilly Property Limited *	UK	Ordinary Share Capital	100%	100%
Lilly Research Centre Limited *	UK	Ordinary Share Capital	100%	100%
Lilly Resources Limited *	UK	Ordinary Share Capital	100%	100%
Eli Lilly Group Pension Trustees Limited **	UK	Ordinary Share Capital	100%	100%

* Held through a subsidiary undertaking

** Held partly through subsidiary undertakings

Eli Lilly and Company Limited is principally engaged in the supply of pharmaceuticals. Eli Lilly Group Pension Trustees Limited acts as trustee of the Group's staff pension plan and has no trading activities.

The remaining subsidiaries at 31 December 2020 have no trading activities other than as attorneys for Eli Lilly and Company Limited. In the opinion of the directors the value of investments in subsidiary undertakings is not less than the amount stated above.

7 Debtors

	Note	2020 £ 000	2019 £ 000
Amounts due from subsidiary undertakings		5,269	5,271

There are no repayment terms for, or interest payable on, the amounts shown above.

8 Creditors

	Note	2020 £ 000	2019 £ 000
Due within one year			
Income tax liability	5	-	2

Eli Lilly Group Limited
Registration No: 01447831

Notes to the Financial Statements for the Year Ended 31 December 2020

9 Share capital and Other reserves

Authorised, Allotted, called up and fully paid shares

	2020		2019	
	No. 000	£ 000	No. 000	£ 000
Ordinary Shares of £1 each	<u>8,350</u>	<u>8,350</u>	<u>8,350</u>	<u>8,350</u>

Other reserves

	2020	2019
	£ 000	£ 000
Capital contribution in 2015	33,021	33,021
Share premium arising on issue of equity shares in 2017	<u>8,750</u>	<u>8,750</u>
	<u>41,771</u>	<u>41,771</u>

10 Dividends

	2020	2019
	£ 000	£ 000
Final dividend paid £0 (2019 - £135,000,000)	<u>-</u>	<u>135,000</u>

11 Parent and ultimate parent undertaking

The company's immediate parent is Lilly Netherland Holding BV, incorporated in Netherlands.

The ultimate parent is Eli Lilly & Company, incorporated in United States of America.

These financial statements are available upon request. The consolidated financial statements of Eli Lilly & Company are those of the smallest and largest group of which the company is a member and for which consolidated financial statements are prepared. The consolidated financial statements can be obtained from Eli Lilly & Company, Lilly Corporate Center, Indianapolis, Indiana, USA.

The company has utilised the exemption under section 33 of Financial Reporting Standard 102 whereby a subsidiary undertaking does not have to disclose transactions with other entities that are wholly owned subsidiaries of the Eli Lilly & Company Group.

Eli Lilly Group Limited
Registration No: 01447831

Notes to the Financial Statements for the Year Ended 31 December 2020

12 Subsequent Events

Following confirmation of the dividend declared by Eli Lilly and Company Limited on 26 July 2021 of £100,000,000 to Eli Lilly Group Limited, the company declared a dividend for £100,000,000 to be paid on 2 August 2021.